Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

A group of health care investors have launched a new advocacy coalition that aims to promote responsible private investment ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...

In a move that will raise eyebrows in Washington, Pfizer has hired the former director of the FDA's Centre for Drug ...

The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

Supporting Rapid Innovation through the PACT Initiative. Pfizer has focused on scientific innovation as a core value since it ...